Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year

B Group added 750,000 shares of ADMA Biologics in Q1, lifting its quarter-end stake to 3.21 million shares valued at $28.90 million, or 21.43% of AUM. The estimated trade was $11.84 million, while the position’s quarter-end value still fell $15.93 million due to the stock’s decline. The filing signals continued institutional confidence despite ADMA shares being down about 58% over the past year.

Analysis

The more important signal here is not the headline buy, but the size of the conviction relative to the fund’s portfolio: a single name now absorbs an unusually large share of reported AUM. That kind of concentration only happens when the manager believes the market is mispricing durability, not just a tactical rebound. In biotech, that often precedes either a multi-quarter rerating if fundamentals keep compounding or a sharp unwind if the next data point breaks the narrative.

The stock’s drawdown has likely forced investors to focus on the wrong variable: near-term product mix rather than earnings power. If the higher-margin franchise keeps offsetting the weaker line item, the market may be underestimating how quickly cash generation can support a higher multiple even in a flat revenue environment. The second-order effect is that any improvement in operating leverage could force short sellers to cover into a thinly owned name, amplifying upside over the next 1-3 quarters.

The key risk is that this remains a story stock until the market sees proof that the favorable mix is durable and not just a temporary trough. If pricing pressure broadens or volume growth stalls, the leverage cuts both ways because concentration cuts both ways for the shareholder base as well. In that scenario, the stock could re-rate lower faster than fundamentals deteriorate, especially if holders who bought on the trough thesis lose patience.

Consensus is probably still too anchored to the one-year chart and not enough on normalized earnings power. The market tends to punish small-cap biotech when one legacy product declines, even if the economics are shifting toward a better-margin mix. That creates a contrarian setup where the risk/reward is better on confirmation than anticipation: wait for the next quarter to validate margin durability, then buy the breakout rather than trying to catch the knife.

Key Decisions for Investors

• Long ADMA on a confirmation basis: buy only on a close above the prior 8-12 week range with volume expansion; target a 15-25% rerating if the market reanchors to cash generation, with a stop below the recent swing low.
• Sell downside skew in ADMA via put spreads out 1-2 quarters if implied volatility remains elevated; the stock has enough fundamental support to make premium-selling attractive, but only sized modestly given headline and execution risk.
• Pair trade: long ADMA / short a basket of weaker plasma or specialty biotech names with deteriorating mix, as a relative-value expression on margin durability rather than absolute direction.
• If already long, trail a stop on a closing-basis breach of the post-earnings support zone; the setup works only if the market keeps paying for earnings quality, so protect against a fast unwind from concentrated ownership.
• For new money, prefer waiting for the next earnings print and guidance update; the best risk/reward is a post-report entry if management confirms the trough thesis and gross margin stays near current levels.